Modification of interferon alpha production
US6962695B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 22, 1999 |
| Grant date | Nov 8, 2005 |
| Priority date | — |
| Expiry date | Dec 22, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/56
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A process for the production of α-interferon comprising the steps: i) inducing of human leukocytes by means of a virus; ii) treating the leukocytes with an enhancing agent selected from: a) Xanthine, pyrimidinol and pyrimidinone or derivatives of anyone thereof, such as theophylline, 2-amino-5-bromo-6-methyl-4 pyriminidol or thymine; b) an organic solvent selected from the group consisting of non-aromatic ketones, aliphatic or cyclic amides, alkylated aliphatic or cyclic urea derivatives and aliphatic or cyclic sulfoxides, such as N-methyl-2-pyrrolidinone, acetone, 2-butanone, 1,3-dimethyl-2-imidazolidinone, dimethylsulfoxide, 4-methyl-2-pentanone-N-ethyl-2-pyrrolidinone, 2-pyrrolidinone, tetramethylene sulfoxide or N,N-dimethylacetamide; or a combination of the compounds from a) with an organic solvent from b).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.